Alluvi, formerly BI 4744, represents a promising development in weight loss care. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide targets demonstrates https://alluvi-healthcare509672.ampedpages.com/alluvi-a-comprehensive-examination-into-retatrutide-s-prospects-70414346